Aspect Biosystems

Aspect Biosystems seeks to revolutionize drug development, personalized medicine, and regenerative medicine by becoming the global leader in 3D human tissue technology. Its disruptive 3D bioprinting platform technology is capable of creating live human tissue on demand. Aspect’s initial products facilitate the development of highly customized physiologically-relevant 3D human tissue models. The idea is to spur the development of completely new therapeutics, and to enable pharmaceutical companies to test drugs that they had shelved previously due to a lack of appropriate models. Aspect plans on licensing out validated tissues from its portfolio and delivering its scale-up bioprinting system to its customers’ facility for in-house and high-volume tissue fabrication.



Tamer Mohamed, Co-founder & CEO

Konrad Walus, Co-founder & CTO